by Karen O'Hanlon Cohrt | Jul 24, 2024 | Trends
In our last article, we introduced mast cells, their origins and morphology, and summarized how they are activated during IgE-mediated allergic responses. Here, we shift gears and explore how mast cells, together with microglia and the blood brain barrier, contribute...
by Karen O'Hanlon Cohrt | Feb 18, 2024 | Trends
Organoids are cell-derived, 3D in vitro models that are cultured to recapitulate structural and functional aspects of the in vivo tissue they are intended to represent. Organoids are not new to research labs, although there has been much hype about them in recent...
by Karen O'Hanlon Cohrt | Nov 21, 2023 | Industry News, Trends
Antibody drug conjugates (ADCs) are targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. In contrast to conventional chemotherapies, which do not discriminate between healthy and cancerous cells, ADCs are...
by Karen O'Hanlon Cohrt | Nov 18, 2022 | Trends
Welcome to our new blog series about the blood brain barrier (BBB)! In Part 1, we will give a brief history on the discovery of the BBB, as well as introduce what we know about its composition and biological functions. The blood brain barrier or BBB is a highly...
by Karen O'Hanlon Cohrt | Dec 18, 2022 | Trends
Welcome back to our blog series about the blood brain barrier (BBB). In Part 1, we provided a brief history on the discovery of the BBB, and introduced what we currently know about its composition and biological functions. In Part 2, we explain why reliable BBB models...
by Karen O'Hanlon Cohrt | Jan 26, 2023 | Trends
Welcome to Part 3 of our blog series covering the blood brain barrier (BBB). In Part 1, we looked briefly at how the BBB was discovered and presented what we currently know about its composition and functions. Part 2 focused on the need for reliable BBB models in drug...
